Status:
COMPLETED
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Eligibility:
All Genders
18-25 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. Growth Hormone in young adults with growth hormone deficiency in childhood. This trial compares a treated group of patients with an untreated group of patients.
Eligibility Criteria
Inclusion
- Child-hood onset growth hormone deficiency
- Subjects received growth hormone replacement therapy during pre-puberty and puberty
Exclusion
- GH treatment during the month preceding randomisation
- Treatment within the previous 6 months with medication that may affect bone mineral density
- Diseases which may affect bone metabolism
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT00184678
Start Date
February 1 2002
End Date
July 1 2006
Last Update
January 13 2017
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Parkville, Victoria, Australia, 3052
2
Novo Nordisk Investigational Site
Auckland, Australia, 1
3
Novo Nordisk Investigational Site
Hamilton, Australia, 2303
4
Novo Nordisk Investigational Site
Subiaco, Australia, 6008